March Recap: Largest Psychedelic Drug Stocks Up Another 5%

Chart, Trading, Forex, Analysis, Tablet, Pc

Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were up 5.4%, on average, in March and are now up 39.9% YTD.

Below are how each constituent stock performed in March, in descending order, and YTD. Plus any recent news, commentary, and/or analysis for each company:

Mind Medicine (MNMD): up 64.3% in March; up 156.8% YTD
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest News, Commentary and/or Analysis:
  - MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
GH Research (GHRS): up 20.5% in March; up 83.8% YTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
  - How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
Atai Life Sciences (ATAI): up 1.5% in March; up 39.7% YTD
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest News, Commentary and/or Analysis:
  - atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
Compass Pathways (CMPS): down 19.0% in March; down 4.9% YTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
  - Compass Pathways Reports Increased Annual Net Loss Amid Clinical Advancements
Incannex Healthcare (IXHL): down 33.9% in March; down 22.6% YTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis: N/A